Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CUDC-101

Small molecule · Inhibitor of histone deacetylase (HDAC9), EGFR and HER2 (ERBB2) · developed by Curis

Phase 1 Most advanced trial (none active)

CRIS Developer

1 Registered trials

What is CUDC-101?

CUDC-101 is a multi-targeted small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2). It is studied in head and neck cancer, with potential to overcome resistance to EGFR and HER2 inhibition through simultaneous inhibition of all three targets.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: histone deacetylase (HDAC9), EGFR, HER2 (ERBB2)
Mechanism: Inhibitor of histone deacetylase (HDAC9), EGFR and HER2 (ERBB2)
Therapy area: Oncology
Developer: Curis, Inc. (CRIS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 1A7Y9MP123

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01384799	Phase 1	Head and Neck Cancer	Completed	CRIS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Cancer

Other drugs acting on HDAC9 / EGFR / ERBB2

Neratinib FDA approved Osimertinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved Actinium Ac 225 FPI-2068 Phase 1 ADCT-502 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 ELVN-002 Phase 1

More from Curis

Cenopodlin Phase 1 Emavusertib Phase 1/2 Fimepinostat Phase 2 GDC-0917 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CRIS page.

Follow CRIS, the company behind CUDC-101

See CRIS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRIS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z